Foundation “Fondation maladie rares“
Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim. Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat.
![](https://utcbs.u-paris.fr/wp-content/uploads/sites/2/2021/09/maple-leaves-background-1.jpg)
Lorem ipsum
Dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim.
© Lorem ipsum dolor sit amet, consectetuer adipiscing
Lorem ipsum dolor sit amet,
dolore magna aliquam
dolore eu feugiat
Lorem ipsum dolor sit amet
cons ectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet
consectetuer adipiscing elit, sed diam Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt.
- Lorem ipsum dolor sit amet
- Lorem ipsum dolor sit amet
- Lorem ipsum dolor sit amet
- Lorem ipsum dolor sit amet
consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim. Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut la
Lorem ipsum dolor sit amet
À lire aussi
![CNRS honors Néovacs and UTCBS, united for a therapeutic RNA vaccine against asthma](https://utcbs.u-paris.fr/wp-content/uploads/sites/17/2024/08/neovacs-logo-2023-lyo.jpg)
CNRS honors Néovacs and UTCBS, united for a therapeutic RNA vaccine against asthma
Suresnes, August 29, 2024 - 8am CET - Neovacs (Euronext Growth Paris : ALNEV), a preclinical-stage biopharmaceutical company developing novel therapies for inflammatory and autoimmune diseases, is honored to be listed among the latest CNRS publications following the...
![Publication in Advanced Science of Preclinical tests obtained with a pFAR plasmid](https://utcbs.u-paris.fr/wp-content/uploads/sites/17/2024/08/Corinne1-1.jpg)
Publication in Advanced Science of Preclinical tests obtained with a pFAR plasmid
Gene Electrotransfer via Conductivity-Clamped Electric Field Focusing Pivots Sensori-Motor DNA Therapeutics: “A Spoonful of Sugar Helps the Medicine Go Down” https://doi.org/10.1002/advs.202401392
![Khair Alareth, Caroline Roques and Nasir Arafath with Nathalie Mignet to present UTCBS’s work at the Controlled release society international congress in Bologna.](https://utcbs.u-paris.fr/wp-content/uploads/sites/17/2024/07/crs-1.jpg)
Khair Alareth, Caroline Roques and Nasir Arafath with Nathalie Mignet to present UTCBS’s work at the Controlled release society international congress in Bologna.
UTCBS presents its work at the international congress of the "controlled release society" in Bologna. The UTCBS team has shown the interest of nanoparticles both for the imaging of ROS in vivo and the promotion of antioxydant therapeutic activity. Caroline Roques...
![The Alnylam Pharmaceuticals 2024 “Interfering RNA & Rare Diseases” Prize has been awarded to Virginie Escriou,](https://utcbs.u-paris.fr/wp-content/uploads/sites/17/2024/06/Sans-titre.jpg)
The Alnylam Pharmaceuticals 2024 “Interfering RNA & Rare Diseases” Prize has been awarded to Virginie Escriou,
The Alnylam Pharmaceuticals 2024 “Interfering RNA & Rare Diseases” Prize has been awarded to Virginie Escriou,